No evidence of association of methylenetetrahydrofolate reductase polymorphism with occurrence of second neoplasms after treatment of childhood leukemia

• Published in: Leukemia & lymphoma 2005-06, Vol.46 (6), p.893-897
• Main Authors: Jazbec, Janez, Kitanovski, Lidija, Aplenc, Richard, Debeljak, Maruša, Dol an, Vita
• Format: Article
• Language: English
• Subjects: Adolescent; Alleles; Antineoplastic Agents - adverse effects; Child; childhood leukemia; Female; Genetic Predisposition to Disease; Genotype; Humans; Infant; Leukemia - complications; Leukemia - drug therapy; Leukemia - pathology; Male; Methotrexate - adverse effects; methylenetetrahydrofolate reductase; Methylenetetrahydrofolate Reductase (NADPH2) - genetics; Neoplasms, Second Primary - etiology; Odds Ratio; Polymorphism, Genetic; Risk; secondary neoplasm; Sequence Analysis, DNA
• ISSN: 1042-8194; 1029-2403
• DOI: 10.1080/10428190500086428

Methylenetetrahydrofolate reductase (MTHFR) polymorphisms have been associated not only with the risk for acute lymphoblastic leukemia (ALL) in adults and children, but also with increased methotrexate toxicity. The present study aimed to investigate whether MTHFR polymorphisms modify the risk for development of secondary malignancies in children treated for ALL with protocols that included high-dose methotrexate. MTHFR genotypes were determined in DNA samples isolated from archived bone marrow smears of 15 patients with a second malignancy and a matched control group of 30 patients who did not developed a second malignancy after the treatment for ALL. The frequencies of MTHFR C677T and A1298C genotypes in all patients were: C677T: CC 40%, CT 46.7% and TT 13.3% and A1298C: AA 46.7%, AC 44.4% and CC 8.9%. The relative risk for second malignancy was not significantly increased in ALL patients having at least one polymorphic C667T [odds ratio (OR) 1.51; 95% confidence interval (CI) 0.43-5.31] or one polymorphic A1298C allele (OR 1; 95% CI 0.29?-?3.46). Our study suggests that MTHFR polymorphisms are not associated with increased risk of second cancer in children treated with high-dose methotrexate.